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Abstract We present a case which highlights several areas of concern relating to
the prevention and management of varicella in Ireland. We review the pathophysi-
ology of this virus and highlight its greater potential for morbidity in certain groups,Migration;
Adult;
Brugada
most particularly adult males. The experience and opinions with regard to varicella
vaccination in the US and other temperate countries is reviewed along with evidence
of changing epidemiology of varicella infection. The National Immunisation Advisory
Committee (NIAC) guidelines are reviewed in the context of our experience.
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1. Introduction
Varicella infection in Ireland, as in the majority
of temperate countries, is generally considered a
benign illness of childhood. This is contrary to our
experience and we present a case which highlights
several areas of concern relating to the prevention
and management of varicella in Ireland. We review
the pathophysiology of this virus and highlight its
greater potential for morbidity in certain groups,
most particularly adult males. The experience and
opinions with regard to varicella vaccination in the
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doi:10.1016/j.jiph.2010.07.001S and other temperate countries is reviewed along
ith evidence of changing epidemiology of vari-
ella infection. The National Immunisation Advisory
ommittee (NIAC) guidelines are reviewed in the
ontext of our experience.
. Case report
K, a 32-year-old man originally from Sri Lanka
igrated to Ireland with his wife 18 months prioro presentation. He had no signiﬁcant past medical
istory. On arrival in the Emergency department,
he patient reported feeling unwell for 2—3 days.
e had a pruritic rash on his face and upper torso
Sciences. Published by Elsevier Ltd. All rights reserved.















































aig. 1 ECG tracing of AK showing features of Brugada
yndrome.
nd complained of epigastric pain for over 24 h. His
eneral Practitioner had diagnosed primary vari-
ella infection (chicken pox) the previous day.
He had a borderline tachycardia with a heart rate
f 100 beats per minute, he was afebrile and his
lood pressure was 140/86.
He was assessed by a senior physician, who
greed with the diagnosis of primary varicella infec-
ion in a non-immune individual. A plan was made
o discharge him on lansoprazole provided an elec-
rocardiogram (ECG) tracing was normal. He was
eassured that chickenpox is a self-limiting illness.
The ECG showed ST elevation in leads V1 and
2 and T wave inversion in lead 3. The patient was
dministered 300mg of aspirin and he was reviewed
y a cardiologist (Fig. 1).
The ECG pattern was consistent with Brugada
yndrome Type 1, a sodium channelopathy which
redisposes people to potentially fatal arrhythmias.
A plan was made for him to be followed up in
he cardiology outpatients when his chicken pox
ad resolved. Electophysiological studies and pos-
ibly ICD (Intracardiac Device) placement would be
onsidered at that time.
While awaiting his paper work at 2 a.m., the
atient collapsed on the ground. He was unrespon-
ive with no palpable pulse and laboured breathing.
eﬁbrillation pads placed on his chest showed a
olymorphic ventricular tachycardia (Fig. 2).
He was successfully resuscitated.








(Fig. 3 Vesicles at various stages of development.
On day 2, the Infectious Diseases Team was con-
ulted. His history was reviewed. He was a 32 year
ld accountant from Sri Lanka, living with his wife
nd 3-week-old daughter, who were both well. He
ad no signiﬁcant medical history. He was on no
egular medications and he had no known drug
llergies. He had no recollection of having had
hicken pox as a child and no recollection of having
ncountered anybody with chicken pox or varicella
oster in the preceding 3 weeks. Given the time-
ine, we suspected that our patient may have been
xposed to varicella in thematernity hospital where
is baby had been born. Having grown up in Sri
anka, he was at an increased risk of contract-
ng this common childhood illness as an adult [1]
Fig. 3).
The National Virus Reference Laboratory was
ontacted who conﬁrmed that the patient’s wife’s
ntenatal varicella serology showed that she was
gG positive, indicative of previous disease. Pas-
ive immunity would be conferred on her baby for
weeks.
It was recommended that he commence acy-
lovir 10mg/kg three times per day intravenously
nd that his temperature be kept under control
ith regular paracetamol. This was of particular
mportance as pyrexia is a recognised precipitator
f arrhythmia in Brugada Syndrome.
The remainder of AK’s in-patient course was
neventful. An ICD was sited on day 9.
. Discussion.1. Virology
umans are the only host of varicella zoster virus













































of the alpha herpes viruses. After replicating at the
port of entry, it spreads via the blood into the skin
and mucosa where further replication takes place,
leading to the typical vesicular rash of varicella
zoster. It then migrates into the sensory ganglia
where it lies latent, liable to becoming reactivated
during times of immunocomprimised to cause her-
pes zoster (shingles). It is susceptible to nucleoside
analogues such as acyclovir, valacyclovir and fam-
cyclovir [2].
3.2. Transmission
In Ireland the incidence of chickenpox is seasonal,
reaching a peak from January to April [3]. The incu-
bation period is from 14 to 16 days (range 10—21).
This may be prolonged up to 28 days in immuno-
comprimised patients and in individuals who have
received IVIG. Cases of chickenpox are highly infec-
tious from 2 days prior to the appearance of a rash
until all of the lesions have crusted, typically 7 days
in total [3]. Zoster is transmissible to non-immune
contacts as chickenpox, but is less infectious than
chickenpox. Transmission is by direct or indirect
contact including inhalation from non-intact vesi-
cles [2].
3.3. Morbidity and mortality
Numerous papers report on the morbidity and mor-
tality associated with varicella [4—8,3].
Adulthood, male gender, pregnancy, smoking and
immunocoprimise confer a higher risk of severe dis-
ease [9—11].
Pneumonia, which has a prevalence of 15—25%
in adults with varicella and an associated mortal-
ity of 11% (and 35% in pregnant patients), develops
1—6 days after the appearance of exanthema [12].
Encephalitis (incidence 1—2/10,000) is a rare com-
plication which can manifest within 7 days and has
a mortality rate of 5—10% [2].
Other complications include visceral dissemi-
nation (pericarditis, colitis, peritonitis, hepatitis,
etc.), neurological extension (deafness, ascending
myelitis, cranial nerve palsies, etc.), ocular (acute
retinal necrosis, uveitis, ptosis, etc.) and bacterial
skin superinfection and septicaemia [2]. Reactiva-
tion of the latent virus causes herpes zoster [7,13].
3.4. TreatmentAntiviral therapy within 24 h of the onset of
the exantham is recommended in all adults with
chickenpox. Early institution of acyclovir ther-
apy is associated with reduction in fever and
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therwise healthy adults with varicella pneumonia
12,14].
Intravenous acyclovir is the standard treatment
or severely immunocomprimised patients [15].
nfections caused by acyclovir resistant VZV strains
hould be treated with parenteral foscarnet ther-
py [16]. The beneﬁt of steroids is yet to be proven
hough steroid therapy (prednisone 60—80mg/day
or 3—5 days) should be considered in VZV vascu-
opathy to reduce inﬂammation [17].
.5. Management of chicken pox contacts
n susceptible immunocompetent adults, VZV dis-
ase may be prevented by post exposure active
accination if applied within 24 h (but up to 72 h)
fter exposure [3,7,18,19]. Patients with vari-
ella may be already infectious 2 days before
he appearance of a rash. As varicella is highly
ontagious, seronegative immunocomprimised or
regnant patients must be protected from patients
ith varicella infection [10]. If they come into con-
act with the virus, it is recommended that they
eceive prophylactic VZV-immunoglobulins, if this
an be given within 96 h of contact [20].
Patients should be managed by immune health
are staff only. This may prove difﬁcult however as
espite NIAC guidelines recommending vaccination
f non-immune healthcare workers, in our large
rban teaching hospital, 5% of Irish staff and up to
5% of Indian and Phillipino nursing staff were non-
mmune [21]. Patients with varicella need isolation
nd exposed healthcare workers should be off work
rom day 10 to 21 post exposure to guard against
urther transmission [18].
.6. Vaccination
n the setting of the morbidity and mortality high-
ighted above, it is useful to examine the effect
hat targeted vaccination has had elsewhere and to
onsider its potential role here in Ireland.
.6.1. The American experience
he Oka strain of the varicella zoster virus was
rst attenuated by Takahashi in 1974 and led to
he development of a live vaccine against chicken-
ox. VZV live vaccines based on the Oka strain have
een recommended as routine in the USA since 1996
nd uptake is closely monitored. Varicella is now
egarded in the US as the leading cause of death
hat could be prevented by vaccine [22].
There is evidence that 15—20% of children do
ot respond immunologically to one dose of vac-
ine and that one dose fails to provide enough of an


























































































1aricella infection and the impact of late entry into
-cell response [23]. Therefore, one dose is admin-
stered at age 1—10 years and two doses 4 weeks
part after the age of 11 years. The vaccination
s well tolerated. Undesirable effects are observed
n 5—35%. About 20% experience local reactions at
he injection site. 3—5% develop a localised or gen-
ralised varicella-like rash [24]. The vaccination
roduces seroconversion in 90—100% and confers
omplete protection on >80% of those vaccinated.
In addition, in the US, the CDC have issued a
tanding order for Nurses and Pharmacists to admin-
ster two doses of varicella vaccine 4 weeks apart
o certain groups including non-US born adults who
ack evidence of immunity [25].
Since 1999, surveillance data in the US has shown
sharp decrease in varicella disease [4]. From 1990
o 1994, the average number of deaths related to
aricella was 145 per annum. The average then
eclined to 66 per annum during 1999—2001. For
eaths in which varicella was listed as the underly-
ng cause, an average decline of 66% was observed
n all age groups under 50 years; from 0.41 deaths
er million to 0.14 per million. The greatest reduc-
ion (92%) was observed among children 1—4 years
f age. This pattern was observed across all races
nd ethnicities. It is held that the program of uni-
ersal childhood vaccination against varicella in the
S had resulted in a sharp decline in the rate of
eath due to varicella [4].
There are still some concerns related to rou-
ine vaccination. Despite the overall reduction in
aricella disease, the incidence of zoster in the US
as not changed [26]. Having the wild-type virus in
he community is thought to reduce the incidence
f shingles in later life. It is postulated that the
ncreasing uptake of varicella vaccine to prevent
hildhood chickenpox may paradoxically increase
he incidence of herpes zoster in older genera-
ions who have had natural varicella and harbour
he virus [27]. Studies evaluating a high potency
aricella zoster vaccine in older persons have been
ncouraging [28,29].
A review article looking at the economics of vari-
ella vaccination programmes, called into question
he credibility of some studies advocating routine
accination. There is a suggestion that univer-
al vaccination of infants is attractive to society
ecause savings occur from averted unproductive
ays for parents [30]. For the healthcare payer,
niversal vaccination of infants does not generate
avings [31]. Most studies reviewed focused on the
trategy of vaccinating children only while their
esults depended heavily on disputable assump-
ions (regarding vaccine effectiveness and impact
n herpes zoster). Since violation of these assump-
ions could have important adverse public health
2
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ffects, pre-adolescent vaccination was suggested
s a more secure alternative [31].
.6.2. Europe
aving observed events in the US, the economic
nd medical burden of VZV in Europe has led to
iscussions regarding both the desirability and fea-
ibility of a similar routine immunisation policy for
ll European children [32]. Rawson et al. concluded
hat in regards to England and Wales, there was
ot sufﬁcient evidence to recommend mass vacci-
ation [5]. Most children get varicella at some time
nd in most cases the consequences are not life
hreatening. Getting it as an adult, when pregnant
r when immunologically compromised generally
esults in severe disease [33]. Childhood vaccina-
ion may lead to an accumulation of susceptible
dults followed by a shift in incidence to those
lder age groups [34] and hence a higher mortality
5].
In an effort to reduce adult susceptibility,
he Society of Independent European Vaccination
xperts (SIEVE) recommended that the immu-
isation of non-immune adolescents needs to
e urgently implemented [35] (this is in addi-
ion to the current recommendations targeting
igh-risk patients, their close contacts with a
egative history of varicella and seronegative
ealth-care workers). A universal policy, opti-
ally incorporating a two-dose schedule was
ecommended to reduce the burden of dis-




Currently in Ireland, there is no vaccination pro-
ram for VZV but there are recommendations for
accine use in certain groups considered at high
isk.
. Non-immune health-care workers without a def-
inite history of chickenpox, proof of immunity
or vaccination status, particularly those working
with haematology, oncology, obstetrical, gen-
eral paediatric or neonatal patients should be
routinely screened for VZ antibody. A history of
chickenpox is less reliable in HCWs from out-
side Western Europe, who are also more likely
to be non-immune and therefore routine testing
should be considered in this group.. Laboratory staff who may be exposed in the
course of their work.
















































4. Children with asymptomatic or mildly symp-
tomatic HIV infection with age speciﬁc CD4
count percentage over 25% should be considered
for two doses with a 3-month interval.
5. Under specialist hospital supervision, certain
immunocomprimised patients.
6. Children in residential units for severe physical
disability.
7. All women of childbearing age without a his-
tory of varicella should have their immunity
checked and those with negative serology should
be vaccinated prior to pregnancy. Pregnancy
should be avoided for 3 months following the last
dose of vaccine. Alternatively, on completion of
pregnancy, those without evidence of immunity
should receive postpartum vaccination.
NIAC recommend vaccination for risk groups
within 3 and possibly up to 5 days post exposure
[3].
3.7. The effect of migration, integration
and the impact on risk
VZV has a global distribution and the primary form
is highly contagious. The prevalence of primary
VZV infection is lower in tropical and subtropical
countries than in Europe and North America and
therefore immigrants to Europe and North America
from the tropics are at increased risk of primary
VZV infection in adulthood [6,9].
Currently only outbreaks of varicella are noti-
ﬁable in Ireland and incidence data are collected
via the General Practice (GP) sentinel practices of
ICGP. More adult patients are being seen in hospital
in recent years. The reasons for this may be due
to increasing numbers of immigrants from tropical
countries, where fewer people have immunity to
chickenpox [36].
Occupational health in Irish Hospitals require
documentation of varicella IgG level prior to tak-
ing up a post and it has been noted that there is an
increasing number of staff from overseas who are
susceptible [21].
Despite this, vaccination is not compulsory and
the vaccine is often declined when offered.
A study amongst the HIV positive patients attend-
ing St. James’s Hospital in Dublin, Ireland looked at
the baseline Varicella IgG status of 594 HIV posi-
tive patients with a view to improving the uptake
of vaccination in the non-immune. It was found
that overall, 91.6% were VZVIgG positive. When the
patients’ geographical origins were compared, it
was seen that 15% of patients from Sub-Saharan
Africa were non-immune. In addition, 4% of the





wS. Feeney et al.
This information identiﬁes a particular at risk
opulation who also present challenges with regard
o vaccinating household contacts due to language
nd cultural differences [37].
A study conducted in England and Wales, showed
hat among those who died from chickenpox, 12%
ere born outside Europe and North America com-
ared with four percent in the general population
f the United Kingdom [5]. At St. Georges Hospital,
ondon, prospectively collected data over 3 years
1998—2001) amongst staff and students, identiﬁed
total of 25 cases of chickenpox. The country of
irth in 22 of these was identiﬁed. Thirteen of the
2 (59%) occurred in people born outside the UK,
hich was disproportionately high since only 39%
f the workforce at St. Georges were black or from
n ethnic background (presumably some of these
ere also born in the UK) [38].
In keeping with the above observations, there
ave been two additional cases of severe vari-
ella associated disease in St. James’s Hospital
ver the past 3 years in males born in South
ast Asia: a 30 year old Indian marketing con-
ultant whose varicella infection was complicated
y acute transverse myelitis and a 38-year-old
ndian man who required mechanical ventilation
or 4 days with a diagnosis of varicella encephali-
is.
In an attempt to objectively quantify the poten-
ial risk in Ireland, the Central Statistics Ofﬁce was
onsulted. Figures from the 2006 census show that
here were over 35,000 persons from Africa liv-
ng in Ireland, 25,000 of whom were between the
ges of 15 and 44 years, and 7800 under the age
f 15 years. In addition, there were 47,000 people
rom Asia, 38,000 of whom were between 15 and
4 years [39]. Of course not all of these are from
ropical areas. One must acknowledge that though
nly a minority of these people are considered to
e an ‘‘at risk group’’ based on the recommen-
ations from the National Advisory Committee on
mmunization (above), a considerable proportion
ill be non-immune (up to 15% in those from cer-
ain areas if we extrapolate from deBarra, 2008). It
s likely, given the age distribution of these persons
hat many will be parents of small children and as
oted above, in the event of a child being infected,
he secondary attack rate for household contacts is
p to 90%.
The NIAC guidelines are recommendations only
nd the onus falls on the individual to ensure they
re vaccinated if appropriate. Non-immune moth-
rs should be identiﬁed antenatally but even in
he event that the guidelines were strictly imple-
ented, a large cohort of seronegative adult males
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.8. Potential targeted vaccination
trategies (Ireland)
. A study amongst healthcare workers found that
a history of chickenpox is a reliable indica-
tor of past infection in temperate climates but
not in those born or raised in tropical climates
(1). A separate study on the cost effective-
ness of varicella serotesting concluded that, in
patients who present to a health care provider
with a negative history of chicken pox, varicella
serology testing is a relatively cost effective pol-
icy for adults but not for school age children
[30]. Therefore, a public awareness campaign
run through schools, the media and health-
care facilities highlighting the potential severity
of varicella in adults could be instituted. This
would advise 1. All non-Irish adult persons to
attend for serology testing and 2. All those
Irish born and reared with no parental or per-
sonal recollection of chickenpox infection, to
attend for vaccination. This option is oppor-
tunistic and places the onus entirely on the
individual.
. Require all new adult immigrants into Ireland to
provide evidence of immunity. This may not be
an acceptable constraint to place on new citi-
zens. It has the potential to reduce the future
burden of chickenpox in adult immigrants but
given that the rate of immigration is slowing and
may soon begin to reverse, it would miss the
large numbers of non-Irish permanently resident
here already.
. Offer vaccination to all school leavers without a
history of chickenpox without serological test-
ing — history alone is likely to be reliable in
Irish persons (1). Serological testing could be
offered to those who immigrated from a tropical
climate.
. Antenatal screening has proven to be excellent
for identifying those vulnerable to infection,
however; a seronegative mother cannot be vac-
cinated until she is post delivery. It seems wise
to screen her household contacts and partner for
evidence of immunity also. This could be imple-
mented by way of a written recommendation to
household contacts to present to their own GP
for serology testing so as not to further burden
maternity units.
. Full vaccination schedule modelled on American
programme. This is unlikely to gain signiﬁcant
support in Ireland where chickenpox is gener-
ally regarded as a benign, self-limiting disease.
It is more likely that we will wait and observe
how varicella vaccination plays out in the
US.
[
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. Conclusion
aricella has the potential to cause signiﬁcant mor-
idity and mortality in particular groups. With
eference to a 32-year-old male patient from Asia,
e have highlighted the importance of early treat-
ent. We outlined the changing epidemiology of
his highly virulent disease in light of migration and
llustrated how healthy adult males are not cov-
red under the current NIAC guidelines. Drawing
n the experiences of other temperate countries,
uggestions for a targeted approach to vaccination
ere made in order to reduce the future burden of
aricella disease in Ireland.
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